Table 1—

Demographics and baseline characteristics of patients with type 2 diabetes receiving glulisine and RHI (ITT population)

VariableGlulisineRHIP
n435441
Sex
    Male244 (56.1)219 (49.7)0.07
    Female191 (43.9)222 (50.3)
Age (years)58.9 ± 10.2057.7 ± 9.900.04
BMI (kg/m2)34.60 ± 6.8834.51 ± 7.020.79
Duration of diabetes (years)14.7 ± 8.1213.4 ± 7.550.02
Age at diagnosis of diabetes (years)44.8 ± 10.3044.8 ± 9.680.86
HbA1c (%)7.58 ± 0.9377.52 ± 0.9590.51
Mean daily insulin dose (units)
    Basal59.6 ± 34.7057.1 ± 31.180.40
    Short acting32.5 ± 25.3631.3 ± 23.570.46
OAD use at randomization245 (56.3)263 (59.6)0.32
Race
    White372 (85.5)376 (85.3)
    Black48 (11.0)51 (11.6)
    Asian8 (1.8)9 (2.0)
    Multiracial7 (1.6)5 (1.1)
    Hispanic origin34 (7.8)26 (5.9)
  • Data are means ± SD or n (%), unless otherwise indicated.